Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2024-02-07 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
国浩律师（南京）事务所关于前沿生物药业（南京）股份有限公司2024年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, and voting procedures of a company's 2024 first extraordinary general meeting (临时股东大会). It details the legality and compliance of the meeting's call, attendance, agenda, and voting results. The document does not contain financial statements or management discussion of financial results, nor is it a report or presentation. It is a formal legal opinion related to a shareholder meeting and the voting process. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official voting results and confirms the validity of the meeting and votes.
2024-02-07 Chinese
前沿生物2024年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as the "2024 First Extraordinary General Meeting (EGM)" materials for a company, including meeting notices, agenda, voting procedures, and a proposal for the election of a non-independent director. It contains detailed information about the meeting process, voting rights, and candidate biography, but it is not a transcript or results announcement. The document is a set of meeting materials provided to shareholders for the EGM. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during general meetings. The document length is 3754 characters, which is consistent with meeting materials rather than a brief announcement or a full report. Therefore, the classification is AGM Information (AGM-R).
2024-01-29 Chinese
前沿生物关于归还前次暂时补充流动资金的闲置募集资金并继续使用部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by a company regarding the use and return of idle raised funds temporarily supplementing working capital. It details board and supervisory approvals, independent director opinions, and compliance with regulatory guidelines. The content focuses on the company's capital management and use of raised funds, not on financial results, audit opinions, or management discussions. The document length is under 5,000 characters and primarily serves as a formal disclosure of capital usage plans and approvals, not a full financial report or detailed investor presentation. This fits the definition of a Capital/Financing Update (CAP) as it updates on the company's fundraising capital usage and related approvals.
2024-01-22 Chinese
前沿生物关于召开2024年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about convening the 2024 first extraordinary general meeting of shareholders (临时股东大会) for a company, including information on meeting date, voting methods, agenda items (such as election of non-independent directors), registration procedures, and proxy forms. It does not contain financial statements or results, nor is it a transcript or presentation. It is not an announcement of voting results but a notice to shareholders about the meeting and how to participate and vote. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document length is about 4,823 characters, consistent with a full meeting notice rather than a brief announcement. Therefore, the classification is AGM Information (AGM-R).
2024-01-22 Chinese
前沿生物2023年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2023 annual performance forecast (业绩预告) for the full fiscal year 2023 (January 1 to December 31, 2023). It provides preliminary estimated financial results including revenue and net profit/loss figures, with explanations of the main reasons for performance changes. It explicitly states that the forecast has not been audited by a registered accountant and that the final audited results will be disclosed in the formal 2023 annual report. The document is relatively short (1712 characters) and serves as a performance guidance or earnings forecast rather than a full financial report. This type of document is best classified as an Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results or forecasts with key highlights only, rather than a full Annual Report (10-K) or Interim Report (IR). FY 2023
2024-01-22 Chinese
前沿生物关于补选董事暨原董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a non-independent director and the subsequent election of a new non-independent director to the company's board. It includes details about the director's resignation, the nomination and election process for the new director, and an independent director's opinion on the matter. There are no financial statements, earnings data, or detailed financial analysis present. The content focuses solely on changes in the company's board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or a certification, so it is not RPA or RNS.
2024-01-22 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.